BIOLOGY |
|
Microenvironmental regulation of survival and growth of B lymphocytes from patients with Chronic Lymphocytic Leukemia (CLL)
Jan Burger, M.D., Ph.D.
University of Texas M. D. Anderson Cancer Center |
|
|
|
Characterization of the Proliferating Compartment in B-CLL Patients and in Healthy Aging Subjects
Nicholas Chiorazzi, M.D.
The Feinstein Institute for Medical Research |
|
|
|
CD38 and the fate of CLL cells: innocent bystander or culprit?
Silvia Deaglio M.D.
University of Torino, Medical School (Italy) |
|
|
|
Role of STAT-3 in Serine Phosphorylation
Zeev Estrov, M.D.
University of Texas M. D. Anderson Cancer Center |
|
|
|
Identification and Characterization of Tumor Initiating Cells in Chronic Lymphocytic Leukemia
Francisco Vega M.D., Ph.D.
University of Texas M. D. Anderson Cancer Center |
|
|
GENETICS |
|
Roles of microRNA in familial chronic lymphocytic leukemia
George Calin, M.D., Ph.D.
Ohio State University/ University of Texas M. D. Anderson Cancer Center |
|
|
|
A study of the poor prognostic genomic alterations affecting 11q and 17p in CLL using CGH arrays
Claire Dearden, M.D.
Royal Marsden Hospital/Institute of Cancer Research (United Kingdom) |
|
|
|
Epigenetic and therapeutic profiling of chronic lymphocytic leukemia
Guillermo Garcia-Manero, M.D.
University of Texas M. D. Anderson Cancer Center |
|
|
|
Dissecting CLL heterogeneity by proteomic analysis
Paolo Ghia, M.D., Ph.D.
Instituto Scientifico San Raffaele (Italy) |
|
|
|
Proteomic characterization of activation induced TCL1-complexes and their targeting as a therapeutic strategy in CLL
Daniel Jones, M.D., Ph.D
University of Texas M. D. Anderson Cancer Center |
|
|
|
Transcriptional activation to target CLL
Deepa Sampath, Ph.D.
University of Texas M. D. Anderson Cancer Center |
|
|
|
Genetic and epigenetic pathways in CLL
Stephan M. Tanner, Ph.D.
The Ohio State University |
|
|
IMMUNOLOGY |
|
Targeting CLL antigens after stem cell transplantation
John Gribben, M.D., DSc.
Barts Cancer Center of Excellence/ The London School of Medicine (United Kingdom) |
|
|
|
Global phenotype profiling of chronic lymphocytic leukemia
Stephen Mulligan, M.B., B.S., Ph.D.
University of Sydney (Australia) |
|
|
|
Immunotherapy with ISF35-Transduced Autologous CLL B Cells
William Wierda, M.D., Ph.D.
University of Texas M. D. Anderson Cancer Center |
|
|
THERAPY/PROGNOSTIC |
|
Validation of Prognostic Biomarkers in CLL
Lynne Abruzzo, M.D., Ph.D.
University of Texas M. D. Anderson Cancer Center |
|
|
|
Targeting ZAP-70 Tyrosine Kinase in Chronic Lymphocytic Leukemia
Januario Castro, M.D.
University of California, San Diego |
|
|
|
Potential Role of FCRL2 as a Surrogate Marker of IgVH Mutation in CLL
Randall S. Davis, M.D.
University of Alabama at Birmingham |
|
|
|
Identifying Therapeutic Targets by Profiling DNA repair in CLL
Alexander Dobrovic, PhD
Peter MacCallum Cancer Centre (Australia) |
|
|
|
Transcription Inhibition to Target CLL
Varsha Gandhi, Ph.D.
University of Texas M. D. Anderson Cancer Center |
|
|
|
Targeting Src-family kinases (SFKs) by membrane-permeant peptides
Michael Hallek, M.D.
University Cologne (Germany) |
|
|
|
Identification of Germline Variants Influencing the Clinical Expression of Chronic Lymphocytic Leukemia
Richard Houlston, M.D., Ph.D.
Institute of Cancer Research (United Kingdom) |
|
|
|
Development of Glycolycin as a novel therapeutic
Peng Huang, M.D., Ph.D.
University of Texas M. D. Anderson Cancer Center |
|
|
|
Pre-Clinical Studies of PEITC as a Novel Agent for Treatment of CLL
Peng Huang, M.D., Ph.D.
University of Texas M. D. Anderson Cancer Center |
|
|
|
A Phase I/II Study of Oral green Tea Extract in Asymptomatic Rai Stage 0-II Patients with Chronic Lymphocytic Leukemia
Neil Kay, M.D
Mayo Clinic |
|
|
|
Application of gold nanoparticles in the treatment of B-Chronic Lymphocytic Leukemia (CLL)?
Priyabrata Mukherjee, Ph.D.
Mayo Clinic |
|
|
|
ZAP-70 methylation: a new prognostic marker in CLL
David Oscier, M.D.
Royal Bournemouth Hospital (United Kingdom) |
|
|
|
MicroRNAs targeting TCL1 as therapeutic agents for B-CLL
Yuri Pekarsky, Ph.D.
Ohio State University |
|
|
|
Novel NF-κB Inhibitors for CLL Treatment
John C. Reed, M.D., Ph.D.
Burnham Institute for Medical Research |
|
|
|
Detailed analysis of cellular response mechanisms after chemotherapy and antibody treatment in biological CLL subgroups
Stephan Stilgenbauer, M.D.
University of Ulm (Germany) |
|
|
SUPPORTIVE CARE |
|
Monitoring of Innate Cellular Immune Response in Chronic Lymphocytic Leukemia- A Pilot Study to Assess Patient Risk of Infection
Dimitrios Kontoyiannis, M.D.
University of Texas M. D. Anderson Cancer Center |
|
|
